Pfizer (PFE) Amortization - Intangibles (2009 - 2026)

Pfizer has disclosed Amortization - Intangibles across 18 years of filings, most recently posting $1.2 billion for Q1 2026.

• In Q1 2026, Amortization - Intangibles fell 2.31% year-over-year to $1.2 billion; the TTM figure through Mar 2026 stood at $4.8 billion (down 5.66% YoY), while the FY2025 annual figure was $4.9 billion, down 7.79% from the prior year.
• Amortization - Intangibles slipped to $1.2 billion in Q1 2026, from $1.2 billion in the prior quarter.
• Over the last five years, Amortization - Intangibles for PFE reached as high as $1.3 billion in Q3 2024 and fell as low as $822.0 million in Q3 2022.
• The 5-year median for Amortization - Intangibles is $1.2 billion (2025), against an average of $1.1 billion.
• Annual changes were most pronounced in 2022 — Amortization - Intangibles retreated 15.08% — and 2023, when it jumped 44.04%.
• A 5-year view of Amortization - Intangibles shows it stood at $822.0 million in 2022, then jumped by 54.14% to $1.3 billion in 2023, then rose by 3.55% to $1.3 billion in 2024, then slipped by 6.25% to $1.2 billion in 2025, then slipped by 3.82% to $1.2 billion in 2026.
• According to Business Quant data, Amortization - Intangibles over the past three periods registered $1.2 billion, $1.2 billion, and $1.2 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.